Abstract
Parathyroid hormone (PTH) plays various important roles in calcium homeostasis and in bone remodeling. PTH induces its biological effects by regulation of gene expression. The intermittent administration of recombinant human PTH has been shown to stimulate bone formation to a higher extent than bone resorption. PTH 1–34 decreases the risk of vertebral and non-vertebral fractures; increases vertebral, femoral, and total-body BMD. PTH promotes hard callus formation and increases bone strength at the site of the fracture. PTH stimulates the proliferation of osteoprogenitor cells and production of alkaline phosphatase and bone matrix proteins that contribute to hard callus formation. PTH promotes osteoclastogenesis by restoring the original shape, structure, and mechanical strength of the bone. Up to date, there are only few published clinical reports studying the effects of PTH on healing of fractures in humans. There are some case reports published that support a beneficial role of PTH use on delayed-unions or non-unions after fractures. We studied the effect PTH 1–84 on the healing course of 65 osteoporotic pubic fractures. Healing at 8 weeks-follow-up was 100% in the PTH group compared to 9.1% in the control group. Patients in the PTH group had significant improvement in functional outcome compared to the control group. Additional results from well-designed and executed clinical studies are needed to clarify the potential effect of PTH on fracture healing in humans.
References
Tenne M, McGuigan F, Jansson L, Gerdhem P, Obrant KJ, Luthman H, Akesson K. Genetic variation in the PTH pathway and bone phenotypes in elderly women: evaluation of PTH, PTHLH, PTHR1 and PTHR2 genes. Bone. 2008;42(4):719–27.
Ellegaard M, Jørgensen NR, Schwarz P. Parathyroid hormone and bone healing. Calcif Tissue Int. 2010;87(1):1–13.
Tenne M, McGuigan FE, Ahlborg H, Gerdhem P, Akesson K. Variation in the PTH gene, hip fracture, and femoral neck geometry in elderly women. Calcif Tissue Int. 2010;86(5):359–66.
Reeve J, Meunier PJ, Parsons JA, Bernat M, Bijvoet OL, Courpron P, Edouard C, Klenerman L, Neer RM, Renier JC, Slovik D, Vismans FJ, Potts JT Jr. Anabolic effect of human parathyroid hormone fragment on trabecular bone in involutional osteoporosis: a multicentre trial. Br Med J. 1980;280(6228):1340–4.
Hosoi T, Miyao M, Inoue S, Hoshino S, Shiraki M, Orimo H, Ouchi Y. Association study of parathyroid hormone gene polymorphism and bone mineral density in Japanese postmenopausal women. Calcif Tissue Int. 1999;64(3):205–8.
Lips P. Vitamin D deficiency and secondary hyperparathyroidism in the elderly: consequences for bone loss and fractures and therapeutic implications. Endocr Rev. 2001;22(4):477–501.
Kronenberg HM. Developmental regulation of the growth plate. Nature. 2003;423(6937):332–6.
Guo Y, Zhang LS, Yang TL, Tian Q, Xiong DH, Pei YF, Deng HW. IL21R and PTH may underlie variation of femoral neck bone mineral density as revealed by a genome-wide association study. J Bone Miner Res. 2010;25(5):1042–8.
Gupta A, Välimäki VV, J Välimäki M, Löyttyniemi E, Richard M, L Bukka P, Goltzman D, Karaplis AC. Variable number of tandem repeats polymorphism in parathyroid hormone-related protein as predictor of peak bone mass in young healthy Finnish males. Eur J Endocrinol. 2008;158(5):755–64.
Duncan EL, Brown MA, Sinsheimer J, Bell J, Carr AJ, Wordsworth BP, Wass JA. Suggestive linkage of the parathyroid receptor type 1 to osteoporosis. J Bone Miner Res. 1999;14(12):1993–9.
Minagawa M, Yasuda T, Watanabe T, Minamitani K, Takahashi Y, Goltzman D, White JH, Hendy GN, Kohno Y. Association between AAAG repeat polymorphism in the P3 promoter of the human parathyroid hormone (PTH)/PTH-related peptide receptor gene and adult height, urinary pyridinoline excretion, and promoter activity. J Clin Endocrinol Metab. 2002;87(4):1791–6.
Scillitani A, Jang C, Wong BY, Hendy GN, Cole DE. A functional polymorphism in the PTHR1 promoter region is associated with adult height and BMD measured at the femoral neck in a large cohort of young Caucasian women. Hum Genet. 2006;119(4):416–21.
Vilariño-Güell C, Miles LJ, Duncan EL, Ralston SH, Compston JE, Cooper C, Langdahl BL, Maclelland A, Pols HA, Reid DM, Uitterlinden AG, Steer CD, Tobias JH, Wass JA, Brown MA. PTHR1 polymorphisms influence BMD variation through effects on the growing skeleton. Calcif Tissue Int. 2007;81(4):270–8.
Wynne F, Drummond FJ, Daly M, Brown M, Shanahan F, Molloy MG, Quane KA. Suggestive linkage of 2p22-25 and 11q12-13 with low bone mineral density at the lumbar spine in the Irish population. Calcif Tissue Int. 2003;72(6):651–8.
Noordin S, Glowacki J. Parathyroid hormone and its receptor gene polymorphisms: implications in osteoporosis and in fracture healing. Rheumatol Int. 2016;36(1):1–6.
Canalis E, Giustina A, Bilezikian JP. Mechanisms of anabolic therapies for osteoporosis. N Engl J Med. 2007;357(9):905–16.
Dobnig H, Turner RT. Evidence that intermittent treatment with parathyroid hormone increases bone formation in adult rats by activation of bone lining cells. Endocrinology. 1995;136(8):3632–8.
Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344(19):1434–41.
Peichl P, Holzer LA, Maier R, Holzer G. Parathyroid hormone 1-84 accelerates fracture-healing in pubic bones of elderly osteoporotic women. J Bone Joint Surg Am. 2011;93(17):1583–7.
Alkhiary YM, Gerstenfeld LC, Krall E, Westmore M, Sato M, Mitlak BH, Einhorn TA. Enhancement of experimental fracture-healing by systemic administration of recombinant human parathyroid hormone (PTH 1-34). J Bone Joint Surg Am. 2005;87:731–41.
Andreassen TT, Ejersted C, Oxlund H. Intermittent parathyroid hormone (1-34) treatment increases callus formation and mechanical strength of healing rat fractures. J Bone Miner Res. 1999;14:960–8.
Holzer G, Majeska RJ, Lundy MW, Hartke JR, Einhorn TA. Parathyroid hormone enhances fracture healing. A preliminary report. Clin Orthop Relat Res. 1999;366:258–63.
Bostrom MP, Gamradt SC, Asnis P, Vickery BH, Hill E, Avnur Z, Waters RV. Parathyroid hormone-related protein analog RS-66271 is an effective therapy for impaired bone healing in rabbits on corticosteroid therapy. Bone. 2000;26:437–42.
Nakajima A, Shimoji N, Shiomi K, Shimizu S, Moriya H, Einhorn TA, Yamazaki M. Mechanisms for the enhancement of fracture healing in rats treated with intermittent low-dose human parathyroid hormone (1-34). J Bone Miner Res. 2002;17:2038–47.
Nakazawa T, Nakajima A, Shiomi K, Moriya H, Einhorn TA, Yamazaki M. Effects of low-dose, intermittent treatment with recombinant human parathyroid hormone (1-34) on chondrogenesis in a model of experimental fracture healing. Bone. 2005;37:711–9.
Komatsubara S, Mori S, Mashiba T, Nonaka K, Seki A, Akiyama T, Miyamoto K, Cao Y, Manabe T, Norimatsu H. Human parathyroid hormone (1-34) accelerates the fracture healing process of woven to lamellar bone replacement and new cortical shell formation in rat femora. Bone. 2005;36:678–87.
Manabe T, Mori S, Mashiba T, Kaji Y, Iwata K, Komatsubara S, Seki A, Sun YX, Yamamoto T. Human parathyroid hormone (1-34) accelerates natural fracture healing process in the femoral osteotomy model of cynomolgus monkeys. Bone. 2007;40:1475–82.
Oteo-Alvaro A, Moreno E. Atrophic humeral shaft nonunion treated with teriparatide (rh PTH 1-34): a case report. J Shoulder Elb Surg. 2010;19(7):e22–8.
Lee YK, Ha YC, Koo KH. Teriparatide, a nonsurgical solution for femoral nonunion? A report of three cases. Osteoporos Int. 2012;23:2897–900.
Aspenberg P, Genant HK, Johansson T, Nino AJ, See K, Krohn K, García-Hernández PA, Recknor CP, Einhorn TA, Dalsky GP, Mitlak BH, Fierlinger A, Lakshmanan MC. Teriparatide for acceleration of fracture repair in humans: a prospective, randomized, double-blind study of 102 postmenopausal women with distal radial fractures. J Bone Miner Res. 2010;25(2):404–14.
Aspenberg P, Johansson T. Teriparatide improves early callus formation in distal radial fractures. Acta Orthop. 2010;81:234–6.
Johansson T. PTH 1-34 (teriparatide) may not improve healing in proximal humerus fractures. Acta Orthop. 2015;15:1–4.
Chesser T, Fox R, Harding K, Greenwood R, Javaid K, Barnfield S, Halliday R, Willett K, Lamb S. The administration of intermittent parathyroid hormone affects functional recovery from pertrochanteric fractured neck of femur: a protocol for a prospective mixed method pilot study with randomisation of treatment allocation and blinded assessment (FRACTT). BMJ Open. 2014;4(1):e004389.
Raghavan P, Christofides E. Role of teriparatide in accelerating metatarsal stress fracture healing: a case series and review of literature. Clin Med Insights Endocrinol Diabetes. 2012;5:39–45.
Chiang CY, Zebaze RM, Ghasem-Zadeh A, Iuliano-Burns S, Hardidge A, Seeman E. Teriparatide improves bone quality and healing of atypical femoral fractures associated with bisphosphonate therapy. Bone. 2013;52:360–5.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer International Publishing AG
About this chapter
Cite this chapter
Holzer, L.A., Holzer, G. (2017). Parathyroid Hormone. In: Rommens, P., Hofmann, A. (eds) Fragility Fractures of the Pelvis. Springer, Cham. https://doi.org/10.1007/978-3-319-66572-6_22
Download citation
DOI: https://doi.org/10.1007/978-3-319-66572-6_22
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-66570-2
Online ISBN: 978-3-319-66572-6
eBook Packages: MedicineMedicine (R0)